|

Loncastuximab tesirine Clinical Trials

7 actively recruiting trials across 6 locations

▼ -1 trial since May 2026

Also known as: ADC ADCT-402, ADCT-402, Anti-CD19 PBD-conjugate ADCT-402, Lonca, Loncastuximab Tesirine-lpyl +5 more

Pipeline

Phase 1: 2Phase 2: 4Phase 2/3: 1

Top Sponsors

  • ADC Therapeutics S.A.2
  • University of Washington1
  • University of Birmingham1
  • M.D. Anderson Cancer Center1
  • Juan P. Alderuccio, MD1

Indications

  • Cancer7
  • Refractory B-Cell Non-Hodgkin Lymphoma2
  • Refractory Diffuse Large B-Cell Lymphoma2
  • Recurrent Diffuse Large B-Cell Lymphoma2
  • B-Cell Non-Hodgkin Lymphoma2

Other1 trial

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Phase 2/3

Clovis, California1 trial

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

University of California San Francisco - Fresno Center for Medical Education and Research

Phase 1

Duarte, California1 trial

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

City of Hope Medical Center

Phase 2

Lynwood, California1 trial

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

The Oncology Institute of Hope & Innovation - Lynwood

Phase 1

Fort Myers, Florida1 trial

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Florida Cancer Specialists and Research Institute

Phase 2

Houston, Texas1 trial

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

MD Anderson Cancer Center

Phase 2

Seattle, Washington1 trial

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.